Brand Name(s): Lodine
CAS nº: 41340-25-4
(eh toe doe lak)

About Etodolac

This new site is dedicated exclusively to etodolac.

It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.

Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about etodolac on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.

This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total etodolac experience! 

Why is this medication prescribed?

Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.

As a group, NSAIDs are non-narcotic relievers of mild to moderate pain of many causes, including injury, menstrual cramps, arthritis, and other musculoskeletal conditions.

Since the response to different NSAIDs varies from patient to patient, it is not unusual for a doctor to try different NSAIDs for any given condition.

See more Product Info

Latest News

Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac

Taro Pharmaceutical Industries Ltd. (“Taro”) reported today that Taro Pharmaceuticals (UK) Limited...

[more]

FDA Safety Changes: Naprosyn/Anaprox and Other Prescription NSAIDs

The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise of the...

[more]

Comparing drugs for arthritis

Several years ago, when my arthritis began acting up, I started taking aspirin to relieve my pain...

[more]

CHMP review of safety of non- selective NSAIDs, EMEA

What are the conclusions of the CHMP on cardiovascular safety of non-selective NSAIDs?

[more]

Taro Receives Approval for Etodolac extended Release Tablets ANDA 400 mg, 500 mg and 600 mg Strengths

Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) reported today that its U.S. affiliate has...

[more]

This site is intended solely for U.S. audiences; products described here may be subject to different medical and/or regulatory requirements in other countries. This site is for educational purposes only; information contained within should not be used to diagnose or treat a health problem or disease. Please consult a licensed health care provider regarding your medical condition.The products mentioned are trademarks of their respective owners.